Immunovant shifts gears, favouring IMVT-1402 over batoclimab in FcRn race
2024-05-30
Immunovant is realigning its clinical development plans, prioritising the next-generation FcRn inhibitorFcRn inhibitor IMVT-1402 as its lead asset over previously touted batoclimab. This decision has led to a postponement of clinical readouts for batoclimab, as the company doubles down on the perceived potential of IMVT-1402 across multiple autoantibody-driven indications.
In a corporate update, Immunovant said it is looking to start four to five potentially registrational studies for IMVT-1402 by the end of March 2025, spanning therapeutic areas such as endocrinology and neurology. By the end of 2026, it hopes to raise that number to a total of 10 indications.
"We are very excited about the immunology market evolution that we believe positions the anti-FcRn mechanism to be the leading therapeutic class across a broad range of autoantibody-driven indications," said CEO Pete Salzmann. "Within the class, we see tremendous opportunity for IMVT-1402, which we believe has a combination of potentially best-in-class features not seen with any other FcRn inhibitorFcRn inhibitor."
More to follow.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。